Chuan Xingxing, Song Qin, Lin Jialiang, Chen Xianhui, Zhang Hua, Dai Wenbing, He Bing, Wang Xueqing, Zhang Qiang
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University , Beijing 100191, China.
Mol Pharm. 2014 Oct 6;11(10):3656-70. doi: 10.1021/mp500399j. Epub 2014 Sep 24.
To address the obstacles facing cancer chemotherapeutics, including toxicity, side effects, water insolubility, and lack of tumor selectivity, a novel stimuli-responsive drug-delivery system was developed based on paclitaxel-loaded poly(ethylene glycol)-disulfide-paclitaxel conjugate nanoparticles (PEG-SS-PTX/PTX NPs). The formulation emphasizes several benefits, including polymer-drug conjugates/prodrugs, self-assembled NPs, high drug content, redox responsiveness, and programmed drug release. The PTX-loaded, self-assembled NPs, with a uniform size of 103 nm, characterized by DLS, TEM, XRD, DSC, and (1)H NMR, exhibited excellent drug-loading capacity (15.7%) and entrapment efficiency (93.3%). PEG-SS-PTX/PTX NPs were relatively stable under normal conditions but disassembled quickly under reductive conditions, as indicated by their triggered-aggregation phenomena and drug-release profile in the presence of dithiothreitol (DTT), a reducing agent. Additionally, by taking advantage of the difference in the drug-release rates between physically loaded and chemically conjugated drugs, a programmed drug-release phenomenon was observed, which was attributed to a higher concentration and longer action time of the drugs. The influence of PEG-SS-PTX/PTX NPs on in vitro cytotoxicity, cell cycle progression, and cellular apoptosis was determined in the MCF-7 cell line, and the NPs demonstrated a superior anti-proliferative activity associated with PTX-induced cell cycle arrest in G2/M phase and apoptosis compared to their nonresponsive counterparts. Moreover, the redox-responsive NPs were more efficacious than both free PTX and the non-redox-responsive formulation at equivalent doses of PTX in a breast cancer xenograft mouse model. This redox-responsive PTX drug delivery system is promising and can be explored for use in effective intracellular drug delivery.
为解决癌症化疗面临的障碍,包括毒性、副作用、水不溶性和缺乏肿瘤选择性等问题,基于负载紫杉醇的聚乙二醇-二硫键-紫杉醇共轭纳米颗粒(PEG-SS-PTX/PTX NPs)开发了一种新型的刺激响应药物递送系统。该制剂具有多种优势,包括聚合物-药物共轭物/前药、自组装纳米颗粒、高药物含量、氧化还原响应性和程序性药物释放。通过动态光散射(DLS)、透射电子显微镜(TEM)、X射线衍射(XRD)、差示扫描量热法(DSC)和核磁共振氢谱(¹H NMR)表征,负载PTX的自组装纳米颗粒尺寸均匀,为103 nm,表现出优异的载药能力(15.7%)和包封率(93.3%)。PEG-SS-PTX/PTX NPs在正常条件下相对稳定,但在还原条件下会迅速分解,如在还原剂二硫苏糖醇(DTT)存在下的触发聚集现象和药物释放曲线所示。此外,利用物理负载药物和化学共轭药物之间药物释放速率的差异,观察到了程序性药物释放现象,这归因于药物的更高浓度和更长作用时间。在MCF-7细胞系中测定了PEG-SS-PTX/PTX NPs对体外细胞毒性、细胞周期进程和细胞凋亡的影响,与无响应的对应物相比,该纳米颗粒表现出与PTX诱导的G2/M期细胞周期阻滞和凋亡相关的优异抗增殖活性。此外,在乳腺癌异种移植小鼠模型中,在等量PTX剂量下,氧化还原响应性纳米颗粒比游离PTX和非氧化还原响应性制剂更有效。这种氧化还原响应性PTX药物递送系统具有前景,可用于探索有效的细胞内药物递送。